CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $23.12M, above the global median of $16.24M
- FinancialsAltman Z-Score 3.3: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.14%
Annual Rate
CNY 0.90Paid annual
Payback Period
30.6 yr
Last Ex-Dividend
Apr 28, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.39BCNY653.10M · vs all stocks (USD)
Trailing P/E
12.90xRevenue (TTM)
3.35BCNY498.31M · vs all stocks (USD)
Profit Margin
10.07%Beta
0.0760xvs all stocks
52-Week Change
-30.64%vs all stocks
Market Capitalization
4.39BCNY653.10M · vs all stocks (USD)
Enterprise Value
3.34BCNY496.51M · vs all stocks (USD)
Trailing P/E
12.90xForward P/E
6.25xPrice to Sales (TTM)
1.31xPrice to Book (MRQ)
1.65xEnterprise to Revenue
0.9960xEnterprise to EBITDA
13.10xGross Margin
65.20%Profit Margin
10.07%Operating Margin
8.50%Return on Assets (TTM)
3.02%Return on Equity (TTM)
12.86%Revenue (TTM)
3.35BCNY498.31M · vs all stocks (USD)
Revenue per Share (TTM)
21.84CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-2.10%Gross Profit (TTM)
2.02BCNY299.76M · vs all stocks (USD)
EBITDA (TTM)
435.24MCNY64.72M · vs all stocks (USD)
Net Income (TTM)
337.40MCNY50.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-20.40%Operating Cash Flow (TTM)
345.27MCNY51.35M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
155.44MCNY23.12M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.9000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
3.14%vs all stocks
Minority Interest (Equity)
20.40MCNYFY2025 · Dec 31, 2025Revenue
3.37BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.40BCNYFY2025 · Dec 31, 2025Gross Profit
1.97BCNYFY2025 · Dec 31, 2025Operating Income
284.48MCNY42.31M · vs all stocks (USD)
Pre-tax Income
391.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
25.84MCNYFY2025 · Dec 31, 2025Net Income
365.22MCNYFY2025 · Dec 31, 2025EBIT
404.25MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
449.94MCNYFY2025 · Dec 31, 2025Research & Development
98.68MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.33BCNYFY2025 · Dec 31, 2025Other Operating Expenses
26.76MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
325.05KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.19MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.37CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.37CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
151.83MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
151.83MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
365.22MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-5.38MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
370.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
270.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
112.53MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
365.22MCNYFY2025 · Dec 31, 2025Other Non-cash Items
35.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.58MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
10.12MCNYFY2025 · Dec 31, 2025Capital Expenditures
-100.29MCNYFY2025 · Dec 31, 2025Purchase of Investments
-6.00MCNYFY2025 · Dec 31, 2025Sale of Investments
19.67MCNYFY2025 · Dec 31, 2025Other Investing Activity
-61.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-147.65MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
85.58MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-111.11MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-141.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.38MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-168.20MCNYFY2025 · Dec 31, 2025Shares Outstanding
153.40MSharesUpdated Aug 20, 2026Float Shares
108.74MSharesUpdated Aug 20, 2026% Held by Insiders
34.87%vs all stocks
% Held by Institutions
4.76%vs all stocks
Total Cash (MRQ)
1.13BCNY167.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.35CNYUpdated Aug 20, 2026Total Debt (MRQ)
95.53MCNY14.21M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0345xCurrent Ratio (MRQ)
1.55xBook Value per Share (MRQ)
17.32CNYUpdated Aug 20, 2026Total Assets
4.53BCNY673.19M · vs all stocks (USD)
Total Current Assets
2.75BCNYFY2025 · Dec 31, 2025Total Liabilities
1.85BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.78BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
114.27MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.74BCNYFY2025 · Dec 31, 2025Cash
110.24MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
113.71MCNYFY2025 · Dec 31, 2025Other Short-term Investments
954.14MCNYFY2025 · Dec 31, 2025Accounts Receivable
780.81MCNYFY2025 · Dec 31, 2025Inventory
286.57MCNYFY2025 · Dec 31, 2025Accounts Payable
642.52MCNYFY2025 · Dec 31, 2025Short-term Debt
61.04MCNYFY2025 · Dec 31, 2025Other Current Liabilities
674.66MCNYFY2025 · Dec 31, 2025Long-term Debt
65.06MCNYFY2025 · Dec 31, 2025Common Stock (Book)
153.40MCNYFY2025 · Dec 31, 2025Retained Earnings
1.83BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.68BCNY398.07M · vs all stocks (USD)
52-Week Low
24.68CNYUpdated Aug 20, 202652-Week High
43.72CNYUpdated Aug 20, 202652-Week Change
-30.64%vs all stocks
Beta
0.0760xvs all stocks
50-Day MA
28.14CNYUpdated Aug 20, 2026200-Day MA
32.32CNYUpdated Aug 20, 2026Avg 10-Day Volume
3.41MSharesUpdated Aug 20, 2026Avg 30-Day Volume
3.56MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
2.22CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.3: safe zoneNotable
Altman Z-Score: 3.30
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $23.12M, above the global median of $16.24MNotable
Levered free cash flow (USD): 23,115,534.746Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule